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Abstract 
During cell entry of an enveloped virus, the viral membrane must be fused with 
the cellular membrane. The virus envelope has a unique structure consisting of 
viral proteins and a virus-specific lipid composition, whereas the host membrane 
has its own structure with host membrane proteins. Compound 136 was 
previously found to bind in close proximity to the viral envelope and inhibit 
influenza virus entry. We showed here that 136-treated influenza virus still 
caused hemolysis. When liposomes were used as the target membrane for 136-
treated viruses, aberrant fusion occurred, few liposomes fused per virion and 
glycoproteins were not distributed evenly across fusion complexes. Additionally, 
large fusion aggregates did not form and in some instances neck-like structures 
were found. Based on previous results and hemolysis, fusion inhibition by 136 
occurs post scission but prior to lipid mixing.  
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Introduction 
 Membrane fusion is involved in a large number of biological processes in 
which contents are brought across the membrane. Membrane fusion is highly 
regulated by specific proteins. In addition, lipid composition is also a determining 
factor for membrane fusion. For infection by enveloped viruses, the membrane 
fusion step during virus entry must ensure that the virus genome is uncircuitously 
delivered to the right location within the host cell. For instance, the entry pathway 
of influenza virus, a negative strand RNA virus that replicates in the nucleus, was 
followed by live imaging 1. Binding of the viral host receptor recognition protein is 
the first step in the entry process. The attached virus particle is internalized in an 
endosome and trafficked to a location near the nucleus. There are three stages 
in the transport process. In the first stage, the virus-bearing endosome moves on 
the actin filaments, followed by dynein-directed translocation to the perinuclear 
region in the second stage. The third stage is an intermittent movement involving 
microtubule-based motilities in the perinuclear region where acidification of the 
endosomal interior occurs. Membrane fusion takes place in a short time frame at 
the end of the trafficking. Along the pathway, host proteins that interact with the 
virus-bearing endosomes, such as Rab5/Rab7 and SNAREs, are recruited to the 
endosome. Rab5 regulates the functions of early endosomes and Rab7 regulates 
the functions of late endosomes on which the entry of influenza virus is 
dependent 2. Before fusion takes place, SNARE complexes must be assembled 
on the endosomes 3. UV-radiation resistance-associated gene (UNRAG), an 
autophagic tumor suppressor, has been shown to be involved in the assembly of 
the SNARE complexes to promote viral fusion with the later endosomes 4. It is 
clear that the fusion of the viral envelope membrane with the endosomal 
membrane during entry is highly regulated by host proteins associated with the 
endosomal membrane. The endocytic virus can program the endosomes to 
recruit specific cognate SNARE proteins onto the target membrane 4. This 
membrane fusion process is not between two lipid vesicles without regulatory 
proteins.  
 
 Changing the membrane structure is an effective way to inhibit viral fusion. 
The interferon-induced transmembrane proteins (IFITMs) have been shown to be 
membrane associated proteins and restrict virus infection 5-8. They assert their 
antiviral effects by changing the properties of the cellular membrane. IFITM3 was 
shown to be targeted to endosomes through its N-terminal region 9, 10. IFITM3 is 
a type II transmembrane protein with a N-terminal intramembrane domain (IM1) 
and a C-terminal transmembrane domain (TM2) flanking a conserved 
intracellular loop (CIL) 8. Overexpression of IFITM proteins increased the lipid 
order, making the membrane less fluidized, which could be reversed by addition 
of oleic acid that generates negative spontaneous curvature 7. IFITM proteins 
also promote accumulation of cholesterol in the late endosomes 11. The exact 
step at which IFITM3 inhibits membrane fusion was recently shown to be the 
pore expansion by altering the cytoplasmic leaflet 12. The accumulated data 
suggest that restriction of the fluidity of the cellular membrane by IFITM proteins 
is an effective mechanism to block viral membrane fusion with the endosomal 
membrane.  
 
 Small molecule inhibitors have been shown to inhibit membrane fusion of 
influenza virus. A number of inhibitor compounds can block conformational 
changes of influenza virus hemagglutinin (HA), which is required for HA to induce 
viral membrane fusion 13. However, these inhibitors are HA subtype-specific. 
Some inhibitors worked on H1 (e.g. RO5464466), or H1-H2 (e.g. BYM-27709, CL 
61917 and Stachyflin), or H3 (e.g. TBHQ, and 4c), respectively. Other fusion 
inhibitors directly bind in the envelope and block viral fusion with cellular 
membranes 14, 15. These compounds appear to change the structure of the lipid 
envelope. 
A potent fusion inhibitor, (Z)-3-(bicyclo[2.2.1]heptan-2-yl)-5-((5-(4’-
chlorophenyl)-3-(3-(piperazin-1-yl)pentyl)furan-2-yl)-methylene)-2-
thioxothiazolidin-4-one, (named compound 136) was shown to block fusion of the 
viral envelope with the cellular membrane16. In this study, we show that 136 
reduces the fusogenicity of influenza virus envelope. 136 appears to alter the 
structure of the viral membrane so it could not fuse with the more rigid 
endosomal membrane as shown by electron microscopic images of lipid-
influenza virus fusion, in contrast to IFITM proteins that restrict the fluidity of the 
cellular membrane to block fusion.  
 
Results 
3.1. Crystal structure 
In previous studies, a potent fusion inhibitor, compound 136, was shown 
to inhibit influenza virus infection (X-31) with an EC50 value of 50 picomolar and a 
selectivity index of 1x106  16. Because of the high potency and selectivity index of 
136, further in vitro characterization was carried out. The crystal structure of a 
compound (7937) that represents the main 136 body indicates that compound 
136 has a rigid configuration and has a similar shape as cholesterol, except for 
the flexible linker (Figure 1, Supplementary Figure S1, Supplemental Table S1).  
3.2. Hemolysis 
In the fusion model proposed by Lee 17, scission of the target membrane 
occurs prior to lipid mixing with influenza virus. Red blood cells (RBCs) have 
been used to study fusion of influenza virus with authentic plasma membranes. 
During the fusion process influenza virus breaks the RBC plasma membrane 
allowing hemoglobin to leak into the bulk solution. The RBCs can be spun down 
and the extent of hemoglobin leakage into the bulk solution can be quantitated by 
measuring the absorbance at 540 nm. Influenza virus treated with DMSO or the 
control compound 211 ((E)- endo/exo-1-(bicyclo[2.2.1]heptan-2-yl)-3- ((5-(4-
chlorophenyl)-3-(5-hydroxy-pentyl)- furan-2-yl)methylene)pyrrolidine-2,5-dione) 
caused hemolysis at a pH of 5.6 or less as anticipated (Figure 1E). Influenza 
virus treated with 136 also induced hemolysis, but to a slightly greater extent at 
pH 5.2-5.8 (Figure 1D). The exact cause for this increase is not clear. We 
speculate that HA molecules in 136-treated virions may be able to aggregate 
somewhat more to induce a slightly increased pore size. The same level of 
hemolysis is achieved at pH 5.0 with DMSO, 211, and 136 treatment indicating 
that scission of the host cell target membrane is not inhibited. Based on a 
previous study16 finding 136 blocks lipid mixing with authentic cellular 
membranes, we conclude that 136 inhibits viral fusion post scission of the target 
membrane but prior to lipid mixing. 
3.3. Electron microscopy 
To directly visualize how 136-treated X-31 virus fused in vitro to 
liposomes, negative stained electron microscopy was performed. As a control, 
136-treated virus and liposomes were mixed at pH 7.5 as shown in Figure 2A. 
Clearly the virus is intact and appears identical to untreated, DMSO, or 211-
treated virus (data not shown). Liposomes are visible as well. Same samples 
were also acidified to pH 5.0 to initiate fusion of virus to liposomes. Most DMSO 
or 211-treated virions fused with liposomes trapping unfused virions (Figure 2B) 
or fused extensively with many virions and liposomes (Figure 2C). The unfused 
viruses in these aggregates are not available to fuse with liposomes simply 
because of steric hindrance by the surrounding fused virus particles and 
liposomes. The portion of DMSO and 211-treated viruses that were not 
incorporated into aggregates fused to liposomes with an even distribution of virus 
glycoproteins in the liposome lipids. Figure 2I shows an example of evenly 
distributed viral glycoproteins in liposome lipids after fusion. Some virus particles 
treated with 136 were able to undergo fusion with liposomes, but the extent was 
greatly reduced (Figure 2D-G). Instead of one particle fusing with multiple 
liposomes in case of the wt virus particles, fusion of influenza virus treated with 
136 usually occurred with just one liposome, and examples of large aggregates 
like those shown in Figure 2B and 2C were not found. In addition, these samples 
had an uneven distribution of viral glycoproteins on the surface of the fused virus 
and liposome membrane as shown in Figure 2D-G. The solid white lines indicate 
the regions where viral glycoproteins are present. Some 136-treated viruses 
were found occasionally to form a neck-like structure (white arrows) by bringing a 
liposomal membrane into close proximity to the viral membrane but did not 
appear to induce lipid mixing (Figure 2E and 2H, white arrows). Similar situations 
were not observed in DMSO or 211-treated samples although it is possible that 
such structures could be present in the large aggregates but are refractory to 
imaging. The neck-like structures between liposomes and 136-treated virus in 
Figure 2E and 2H may reflect how scission of the target membrane could occur 
but lipid mixing is blocked at cellular membranes.  
3.4. Lipid mixing 
To gain further insight of how 136 blocks fusion to cellular membranes we  
tested lipid mixing of DiD labeled X-31 virus with liposomes by lowering the pH 
and monitoring the dequenching of DiD for 20 minutes. Samples treated with 
DMSO or 211 dequenched similarly (Figure 3). The initial lipid mixing took place 
faster then what could be measured by our instrument. Samples treated with 136 
dequenched at a slower initial rate, but all the samples achieve the same extent 
of dequenching after 20 minutes. Importantly, 136 quenched the DiD baseline 
fluorescence to a further extent than when DMSO or 211 was used to treat 
viruses. The baseline at pH 7.5 with DMSO or 211 is about 305 fluorescence 
units, and with 136 the baseline shifts to about 230 fluorescence units. The 
quenching of DiD at the baseline suggests that 136 binds to the virion in close 
proximity to DiD in the viral membrane. 
3.5. Content mixing 
Based on 136-treated influenza virus mixing lipids with liposomes, we 
decided to quantitate content mixing in the liposome system using the same virus 
and liposome concentrations as Figure 2. To accurately quantitate the extent of 
content mixing, we encapsulated the liposomes with trypsin and initiated the 
fusion reaction (Figure 4). If trypsin inside the liposomes was able to mix with the 
contents of the virus then trypsin would degrade the M1 and NP proteins. If 
trypsin was to leak outside of the liposomes then it would degrade HA. Because 
trypsin is a 23-kDa protein, a large pore connecting the lumen of the liposome to 
the interior of the virus must be present if M1 and NP are degraded. We found 
that DMSO and 211-treated viruses allowed approximately half of the M1 and NP 
proteins to be degraded in the sample. We believe that the aggregation caused 
by extensive fusion between the liposomes and virus prevented further 
degradation of the M1 and NP proteins. Interestingly, with 136-treated virus we 
saw an increase (one way ANOVA, post-hoc Tukey test, P < 0.01) in trypsin 
digestion of M1 and NP but not of HA as compared to DMSO and 211-treated 
samples. Virus treated with 136 can undergo more content mixing during fusion 
to liposomes due to less aggregation in comparison with DMSO and 211-treated 
viruses, but fusion is arrested during fusion to cellular membranes. This suggests 
the composition of the target membrane is a critical factor for inhibition by 136. 
Aggregation trapping unfused virions and liposomes explains why 211 and 
DMSO treated samples exhibited less content mixing (Figure 2C). 
 
Discussion 
 Fusion inhibition by small molecules is a promising mechanism to target 
with antiviral agents 18. Compound 136 was previously shown by live imaging to 
be a potent inhibitor that prevents fusion of influenza virus with the cellular 
membrane16. Trypsin-digestion studies further revealed that the inhibitors do not 
destroy the viral envelope, destabilize hemagglutinin (HA), or prevent the low pH-
induced conformational change of HA.  
The EM images of X-31 virus with and without treatment with 136 revealed 
two different modes of membrane fusion with liposomes. The virus treated with 
DMSO or 211 was robust in fusion with liposomes. One virus particle was shown 
to fuse with multiple liposomes to form large aggregates (Figure 2B). On the 
other hand, the virus treated with 136 appeared to have lost its high fusion 
potential even though fusion with liposomes was not completely blocked. This 
observation is consistent with the result from our studies on 136-treated viruses 
with cellular membranes in which fusion was reduced to 20% of untreated 
viruses 16. The 136-treated virus could not fuse with many liposomes to form 
large fusion aggregates like the 211-treated virus. In cases that aberrant fusion 
occurred, the glycoproteins were not distributed across the whole membrane 
(Figure 2D - 2G). Sometimes 136-treated virus fusion could not proceed to 
completion (Figure 2E and 2H). This may reflect how the fusion process was 
arrested when authentic cellular membranes were used as target membranes16.  
In vitro studies of 136-treated influenza virus suggests that the structure of 
the viral envelope was changed by binding of 136 to the virion. The baseline 
fluorescence of DiD labeled virions was further reduced by treatment with 136 
but not 211 or DMSO, suggesting that 136 binds in close proximity to the 
membrane bound DiD (Figure 3). Lipid mixing of DMSO, 136, or 211-treated DiD 
labeled virus with liposomes occurred to the same extent although the initial rate 
of lipid mixing was slower in 136-treated samples (Figure 3). This observation 
can be explained by the pattern of the 136-treated virus with liposomes. Since no 
aggregates or trapped virions were present, the lipid mixing could be initiated 
simultaneously between a large number of virions and liposomes. The initiation 
of lipid mixing occurred more slowly at the beginning due to inhibition by 136, but 
eventually lipid mixing reached the same extent as 211-treated virus. The content 
exchange between the 136-treated virus and liposomes with encapsulated 
trypsin was also more complete because of the same reason (Figure 4). 
During enveloped virus assembly, the virus buds at the host cell 
membrane. For viruses like influenza virus, the viral glycoproteins and other 
envelope proteins are concentrated at membrane microdomains 20. In the 
released virus progenies, the virus envelope has a lipid composition rich in 
sphingolipids and cholesterol, which is very different from the cellular membrane 
21. It has been shown that the cholesterol content in the membrane has various 
effects on the fusion kinetics of enveloped viruses 22. It is also shown that the 
transmembrane domains of viral glycoproteins play an important role in the 
fusogenicity of the viral envelope 23. The unique structure of the viral envelope is 
constructed with virus-specific lipid composition and the transmembrane domains 
of viral glycoproteins 24. Fusion inhibitors like compound 136 may bind in the viral 
envelope, reduce fusogenicity of the virus, and block fusion post scission but 
prior to lipid mixing with cellular membranes.  
 From previous studies we found that 136 blocks lipid mixing of influenza 
virus with the endosomal membrane of human lung epithelial cells 16. 
Additionally, when 136-treated influenza virus was fused at the plasma 
membrane of human lung epithelial cells analogous to the liposome assays 
performed in this work, lipid mixing was blocked16. Here we have narrowed down 
the step of the fusion pathway blocked by 136 to post scission of the host cell 
membrane and prior to lipid mixing. In vitro liposome fusion assays revealed that 
136-treated viruses lost their high fusion potential and exhibited aberrant fusion 
to liposomes with limited distribution of viral glycoproteins. In some instances the 
136-treated virions did not complete fusion; instead a neck-like structure between 
the viral membrane and the liposomal membrane was present. This may reflect 
how fusion is arrested by 136 at the plasma membrane and endosomal 
membranes of human lung epithelial cells.  
 
Methods 
2.1. Crystallization.  
A vial in a vial technique was used to crystallize compound 7937. The 
inner vial contained 0.5 mL of 25 mg/mL 7937 dissolved in chloroform. The outer 
vial contained 4.5 mL of pentane. The outer vial was sealed then left at room 
temperature for one week. Large single crystals appeared in the inner vial within 
1 week. Crystal were shipped to the X-ray Crystallography Center at Emory 
University for structure determination. 
2.2. Cells and viruses.  
MDCK-2 cells were cultured in EMEM supplemented with 5% FBS and 
penicillin/streptomycin. All influenza viruses were grown in MDCK-2 cells. 
Influenza virus strain X-31 (H3N2) was amplified by infecting confluent MDCK-2 
cells at an MOI of 0.001. Viruses were purified on a 20-50% sucrose gradient by 
centrifugation for 1.75 hours at 60,000 RCF.  
2.3. Preparation of liposomes and fluorescently labeled virus. 
 Similar as in Schmidt et al. 25, POPC, POPE, and cholesterol were 
dissolved in chloroform:methanol (2:1) to make stock solutions. Liposomes 
composed of POPC:POPE:cholesterol (1:1:2) were made by mixing aliquots of 
the POPC, POPE, and cholesterol stock solutions in a glass vial. The solvent 
was evaporated with a stream of nitrogen leaving a thin film of lipids on the 
bottom of the glass vial. Residual solvent was removed by leaving the samples 
under high vacuum (less than 10 µm mercury) overnight. To produce 100 nm 
unilamellar liposomes, samples were hydrated at 2 mg/mL in 10 mM HEPES, 
100 mM NaCl, pH 7.5. The hydrated liposomes were subject to 5 cycles of 
freeze-and-thaw using liquid nitrogen and a 37˚C water bath, then extruded 
through a 100 nm diameter polycarbonate filter 21 times (Avanti Polar Lipids). X-
31 virus was labeled with DiD by directly adding a 5 µL aliquot of DiD Vybrant 
solution to 500 µL of 2 mg/mL virus sample. Labeling was performed for 2 hours 
at 37˚C with constant shaking. Unincorporated dye was removed by 
centrifugation at 60,000 RCF for 30 minutes and the pellet was resuspended in 
10 mM HEPES, 100 mM NaCl, pH 7.5. 
2.4. Fusion assays with liposomes and fluorescently labeled virus.  
X-31 virus was preincubated for 20 minutes with various concentrations of 
136, 211, or DMSO only. Liposomes were added to the sample to a final 
concentration of 40 µg/ml X-31 virus and 1.5 mg/mL liposomes. To initiate fusion, 
the pH of the mixture was reduced to 5.0 using an aliquot of 10 mM HEPES, 100 
mM NaCl, 50 mM Citrate, pH 3.0. Fusion progress was monitored by 
fluorescence measurements of DiD at λEX =644 nm/λEM=665nm. All fluorescence 
measurements were performed with continuous data collection for 20 minutes 
using a Cary Eclipse spectrofluorometer (Varian). The intensity of fluorescence 
was normalized by adding aliquots of Triton X-100 to each cuvette and recording 
the maximal fluorescence measurements. The formula for normalizing 
fluorescence measurements was [F(t)-F(0)]/[FTX-100-F(0)] where F(t) is the 
fluorescence intensity at a time point, F(0) is the initial fluorescence 
measurement, and FTX-100 is the maximal fluorescence measurement after adding 
Triton X-100. 
2.5. Hemolysis assay.  
1 µL aliquots of inhibitor stocks were added to the wells of a 96 well plate. 
As a control 1 µL of DMSO only was added to wells. Next, 100 µL of X-31 virus 
at 108 pfu/mL was added to the wells and mixed. 100 µL of chicken red blood 
cells in DPBS was added to each well at a final concentration of 1% and 
incubated at 37˚C for 10 minutes. The plate was subject to centrifugation at 3000 
rpm for 2 minutes and the supernatant was removed. To initiate hemolysis, 250 
µL of 138 mM NaCl 10 mM citrate, pH 5.0 – 6.0, was added to the appropriate 
wells. To establish the baseline level of hemolysis, 138 mM NaCl 10 mM HEPES, 
pH 7.5, was added to a well. The plate was placed in an incubator at 37˚C for 10 
minutes. Cells were pelleted at 3000 rpm and 200 µL of supernatant was 
transferred to a new 96 well plate. OD540 was measured using a Biotek Synergy 
HT plate reader.  
2.6. Negative stain electron microscopy. 
 Equal volume of 10 µg/mL X-31 virus and 250 µg/mL liposomes were 
mixed, acidified with an aliquot of 50 mM citrate pH 3.0, and incubated for 20 min 
at 37˚C. Samples were reneutralized with an aliquot of 100 mM Tris pH 10.0 and 
incubated at 37˚C for 1 hour. 7 µL of sample was applied to a glow discharged 
carbon coated grid for 30 seconds, blotted with filter paper, stained with 7 µL of 
1% phosphotungstic acid pH 7.5 for 20 seconds, and blotted again. Samples 
were imaged with a FEI Tecnai 12 transmission electron microscope 
2.7. Trypsin mixing assay.  
Liposomes were prepared as above except 10 mg/mL trypsin was 
included during hydration and freeze thawing was omitted to preserve enzymatic 
activity. Excess trypsin that was not encapsulated into liposomes was removed 
by dialysis and trace amounts of trypsin were removed by passing the liposomes 
over a 2 mL STI-agarose conjugated column (GE healthcare) according to the 
manufactures instructions. Equal volumes of 10 µg/mL X-31 virus and 250 µg/mL 
liposomes were mixed, acidified with an aliquot of 50 mM citrate pH 3.0, and 
incubated for 20 min at 37˚C. Samples were reneutralized with an aliquot of 100 
mM Tris pH 10.0 and incubated at 37˚C for 1 hour. The reaction was terminated 
by addition of 2 mM AEBSF for 20 minutes at 37˚C. The samples were 
electrophoresed on a 10% nonreducing polyacrylamide gel. Gels were stained 
with SYPRO ruby, and imaged with a ccd based gel imager (Syngene G:box). 
ImageJ was used for quantitation of protein bands. 
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AEBSF,  4-(2-Aminoethyl)benzenesulfonyl fluoride;  
CIL, conserved intracellular loop;  
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HA, hemagglutinin;  
IFITM, interferon-induced transmembrane protein;   
IM1, intramembrane domain 1;  
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RBC, red blood cell;  
SNARE, Soluble N-ethylmaleimide-sensitive factor activating protein receptor;  
STI, soybean trypsin inhibitor;  
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Figure Captions 
Figure 1. Structure of compounds 136 and 211, and the crystal structure of 
a related compound, and hemolysis analysis. (A) and (B) Line drawings of 
the chemical structure of compounds 211 and 136, respectively. (C) Crystal 
structure of compound 7937, a compound analogous to 136. Due to the flexible 
aliphatic chain of 136 it was not successfully crystallized. (D) Hemolysis assays 
were conducted with 136 or (E) 211-treated viruses. Because hemolysis requires 
concentrated virus, 0.2 µM is the EC50, 0.6 µM is the EC90, and 1.2 µM is the 
EC99 for 136. 136 treatment at pH 5.8 caused significantly different hemolysis (P 
< 0.01) between all samples. Treatment with 136 caused significantly more 
hemolysis at pH 5.2 to 5.6 (one way ANOVA, post-hoc Tukey test, P < 0.05) as 
compared to DMSO. Hemolysis was not affected by treatment with 211. At pH 
5.0 hemolysis is equivalent in all samples. Representative data shown of 2 
independent experiments. Data points are the average of 2 replicates ± SD.  
 
Figure 2. Fusion of 136-treated virus with liposomes results in less 
aggregation and uneven glycoprotein distribution.  
136-treated virions and liposomes at pH 7.5 (A). All other samples had the same 
concentrations of virions and liposomes, and were acidified to pH 5.0. (B) Most 
211-treated virions fused with liposomes trapping unfused virions or (C) fused 
extensively with many virions and liposomes. 136-treated virions fused to 
liposomes but uneven glycoprotein distribution was observed. (D-G, I) White 
lines indicate continuous glycoproteins stretches on the surface of fused virions 
and liposomes. (E, H) Some 136-treated virions form a neck-like structure that 
was not observed in 211-treated samples. The white arrows point to the neck 
structures. (I) Complete fusion with 211-treated virions and liposomes show even 
glycoprotein mixing. Scale bar: 100 nm. 
 
Figure 3. 136 quenches DiD baseline fluorescence and affects the lipid 
mixing rate.  
DiD labeled X-31 virus was fused to liposomes by lowering the pH. The reaction 
progress was monitored as an increase in fluorescence intensity due to 
dequenching of DiD as it mixes with liposome lipids. As a negative control 
dequenching at pH 7.5 was measured. The baseline fluorescence at pH 7.5 is 
the same for DMSO and 211-treated samples but the fluorescence signal is 
significantly quenched by 136. The initial rate of dequenching was slowed by 136 
treatment of virions. Final dequenching was nearly identical for all pH 5.0 
samples. A 5 point moving average was applied to all samples to smooth the 
data.  
 
Figure 4. 136-treated virions mix contents with liposomes. Inhibitor treated 
X-31 virus was fused to liposomes containing trypsin or empty liposomes as a 
control. The level of each protein was normalized to the control sample of X-31 
virus and liposomes without trypsin (DMSO no tryp). DMSO and 125 nM 211-
treated virions both showed that approximately 50% of NP and M1 were 
degraded by trypsin. 125 nM 136-treated virions (125 nM was used to make sure 
99% virions were treated by 136) showed apparently more degradation of NP 
and M1 by trypsin (one way ANOVA, post-hoc Tukey test, P < 0.01). When Triton 
X-100 was added to 136-treated samples complete degradation of all proteins 
occurred (TX). 
 
 




